Good morning dispensers of wisdom!
Roombas have officially become microscopic. Researchers have built tiny robotic cleaners that can be steered through liquid using nothing but light, sweeping up bacteria as they go. And tiny really does mean tiny: the nanorobots are smaller than a single bacterium and roughly 50 times smaller than the width of a human hair. By changing the polarization of a laser, researchers can make them turn, travel along precise routes and use heat-generated forces to attract nearby bacteria. In experiments, the little cleaners rounded up E. coli and Staphylococcus, carried surprisingly large bacterial clusters around and then released their haul when the light was switched off. The technology is still firmly in the laboratory, but researchers say it could eventually help scientists manipulate cells and microbes at scales that are otherwise extremely difficult to reach. Somewhere, a Roomba just looked at its career prospects and got nervous.
Let’s get into it.
Staying #Up2Date 🚨
1: Is It Time to Rethink Tamsulosin?
A small JAMA Network Open trial found about 1 in 3 older men taking tamsulosin had little or no symptom benefit, despite many believing the drug was helping. With just 30 participants attempting the full protocol, the findings aren’t practice-changing, but they do raise a useful deprescribing question: does that longstanding tamsulosin prescription still need to be there?
2: Semaglutide Keeps Appetite Down
A 60-week randomized trial found semaglutide’s appetite effects may have staying power. Adults receiving semaglutide 2.4 mg consumed roughly 24% to 30% fewer calories than those taking placebo at follow-ups through week 60. The findings suggest semaglutide’s effects on food intake persist well beyond the early months of treatment, even as weight loss begins to plateau.
3: CagriSema Makes Its Case in Diabetes
The phase 3a REIMAGINE 1 trial tested CagriSema, combining cagrilintide with semaglutide, in adults with type 2 diabetes. After 40 weeks, the higher dose cut HbA1c by about 1.8 percentage points and body weight by 13.8%, significantly outperforming placebo. CagriSema remains investigational, but combining GLP-1 and amylin activity could be one to watch.
Shelf Watch 🏥
Drug Shortages ⚠️
-
Company: Taro Pharmaceuticals
-
Drug class: Corticosteroids, combination with antibiotics
-
DIN: 00717002
-
Strength affected: 1MG 0.25MG 100000UNIT 2.5MG
-
Shortage status: Actual shortage
-
Reason for shortage: Disruption of the manufacture of the drug
-
Start date: 2026-07-15
-
Date updated: 2026-08-17
-
Estimated end date: 2026-09-04
-
Company: Taro Pharmaceuticals
-
Drug class: Androgens
-
DIN: 002463792
-
Strength affected: 1%
-
Shortage status: Actual shortage
-
Reason for shortage: Disruption of the manufacture of the drug
-
Start date: 2026-08-04
-
Date updated: 2026-08-17
-
Estimated end date: 2026-08-28
Newly Approved Drugs ✨
Etcamah (Camizestrant): Next-generation oral selective estrogen receptor degrader (SERD) indicated in combination with a CKD4/6 inhibitor for the treatment of hormone receptor positive, locally advanced or metastatic breast cancer upon detection of Estrogen Receptor 1 mutation (ESR1m) during firstline aromatase inhibitor (AI)- based therapy.
-
DIN: 02570572
-
NOC date: 2026-08-04
-
Submission type: New active substance (NAS), new drug submission (NDS)
-
Manufacturer: Astrazeneca Canada
-
Product type: Anti-estrogen
-
Dosage form: Tablet (75 mg) (oral)
💰 Take the Survey, Get Paid $25
Have 10 minutes? Power of VAX wants to hear from Canadian pharmacists, with a $25 honorarium for the first 1,000 pharmacists who complete the survey.
Power of VAX is a pharmacist-focused program designed to strengthen vaccination practices and improve patient outcomes. Your answers about day-to-day practice will help shape this year’s program around what pharmacists actually need.
And it has some solid results behind it. Last year, participating pharmacists saw a 3x improvement in vaccination effectiveness, and the program earned the FIP Seal, a mark of quality and professionalism in pharmacy education from the International Pharmaceutical Federation.
The survey closes August 21 and the honorariums are limited. So if you want in, sooner is better.
A Leg Up on Nerve Pain
How one hospital is helping amputees fight painful neuromas
What happened: A first-of-its-kind Ontario program is taking a page from a cancer treatment to relieve pain for amputees.
Why it matters: More than 200,000 Canadians live with limb loss or limb difference. After an amputation, severed nerves can develop into painful bundles of tissue called neuromas, sometimes causing chronic pain for years. Now, Hamilton General Hospital is freezing those nerves into submission.
Cryoablation is a minimally invasive procedure that can take about 20 minutes. It involves a very cold probe to freeze the nerves that cause pain at the amputation site. The probe inserted through tiny cuts rather than a large incision. Although the program is new, the procedure isn’t; it’s been used for years to treat cancer tumours and vascular malformations.
After looking at cases from the US and Japan, an interventional radiologist discovered that the same cryoablation technology could be safely adapted to treat painful neuromas that can occur after an amputation. Since the breakthrough, 35 patients have been treated through the new program at Hamilton General Hospital, with an 85% success rate.
But: Researchers haven’t yet tracked long-term effects for amputee patients who recieved cryoablation therapy. One man who participated in the procedure said the pain gradually began to creep back up a few months later, proving that the treatment isn’t permanent. The technique also carries risks, such as infection and bleeding. Since the surgery uses a frozen probe, there’s also a chance of skin burns similar to frostbite.
Bottom line: One of the golden rules in life is sharing, and that teaching works for medicine too. Even though the surgery isn’t a cure, patients say cryoablation therapy has helped sleep through the night, some for the first time in decades.
Hot Off The Press 🗞️
1: 🇨🇦 Giving a liver a second chance might give a patient one, too: a Quebec man just became the first patient in North America to undergo a liver transplant using new “regeneration” technology. At Montreal’s CHUM, surgeons used the Liver Assist system to circulate oxygen-rich fluid through a donated liver that might otherwise have been considered too risky to transplant, then tested how it functioned under blood-based conditions meant to mimic the body. CHUM performs about 70 liver transplants a year and estimates the machine could make 20 to 24 additional livers available in its first year alone. That would amount to roughly a third of the centre’s current annual transplant volume.
2: 👩⚕️ The Lindsay Clancy trial is putting postpartum psychosis in the spotlight, and raising difficult questions about how the rare but severe condition is recognized. Clancy’s defence argues she was experiencing postpartum psychosis when her 3 children died in 2023, while prosecutors argue she acted intentionally and deliberately. The case has renewed attention on a condition that can emerge rapidly after childbirth and requires urgent psychiatric care. Clancy repeatedly sought mental-health treatment before the deaths, making the trial a conversation about recognition and maternal mental-health care as much as a legal one. The trial has already put a little-known psychiatric emergency before a much bigger audience.
3: 💉 America’s vaccine shake-up may not stop at the border. US President Donald Trump has called for major changes to the childhood vaccine schedule, including spacing out routine immunizations and eventually separating the MMR vaccine into individual shots, despite opposition from major medical groups. The concern for Canada isn’t that our schedule automatically follows suit. NACI develops Canadian guidance independently, and provinces and territories make their own program decisions. But experts warn the US shift could still spill north through vaccine misinformation and hesitancy, particularly as Canada continues to deal with measles outbreaks.
RxBriefly Picks 💊
📚 Learn: what’s new in topical treatment for plaque psoriasis. This free 30-minute course covers where corticosteroids and newer nonsteroidal options fit, plus practical guidance on setting treatment expectations, safety and long-term management.
🌿 Make: something with those fresh herbs currently taking over your garden. Canadian Living has 20 recipes, from lemony tomato basil pasta and classic pesto to strawberry-rhubarb basil crisp and apple-mint-lime granita.
📖 Read: one more book before summer slips away. The Guardian asked a group of authors to pick their perfect summer reads, with everything from twisty thrillers and dark fiction to memoirs and easy-to-devour novels. Consider this permission to squeeze in one last summer read.
📺 Watch: a very Canadian night in music history. CBC Gem is bringing back The Tragically Hip: A National Celebration on Aug. 22, marking 10 years since the band’s final hometown performance in Kingston. It’ll stream commercial-free, so maybe keep Saturday night open.
🎡 Visit: the Canadian National Exhibition, which officially kicks off another season of rides, concerts, midway games and gloriously questionable fair food this Friday.
Relax 🧩
First clue: __ tech, OR personnel
Need a rematch? We’ve got you covered. Check out our Crossword Archive to find every puzzle we’ve ever made, all in one place.
Think you crushed it? Challenge your pharmacist friends to beat your time.
Meme Of The Week 😂
Advertise with RXBriefly 📣
Want to reach thousands of Canadian pharmacists every week? Email [email protected] to learn more.
Help Us Get Better 🙏
That’s all for this issue.
Cheers,
The RxBriefly team.